Financials data is unavailable for this security.
View more
Year on year Siegfried Holding AG had net income fall -27.93% from 156.49m to 112.78m despite a 3.41% increase in revenues from 1.23bn to 1.27bn. An increase in the selling, general and administrative costs as a percentage of sales from 3.51% to 8.48% was a component in the falling net income despite rising revenues.
| Gross margin | 25.87% |
|---|---|
| Net profit margin | 10.03% |
| Operating margin | 13.85% |
| Return on assets | 7.06% |
|---|---|
| Return on equity | 14.98% |
| Return on investment | 8.64% |
More ▼
Cash flow in CHFView more
In 2023, cash reserves at Siegfried Holding AG fell by 35.12m. However, the company earned 208.61m from its operations for a Cash Flow Margin of 16.41%. In addition the company used 146.86m on investing activities and also paid 94.75m in financing cash flows.
| Cash flow per share | 49.93 |
|---|---|
| Price/Cash flow per share | 24.46 |
| Book value per share | 211.39 |
|---|---|
| Tangible book value per share | 200.69 |
More ▼
Balance sheet in CHFView more
| Current ratio | 2.70 |
|---|---|
| Quick ratio | 1.40 |
| Total debt/total equity | 0.4742 |
|---|---|
| Total debt/total capital | 0.3217 |
More ▼
Growth rates in CHF
Year on year, growth in dividends per share increased 5.88% while earnings per share excluding extraordinary items fell by -26.87%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 0.48% |
|---|---|
| Div growth rate (5 year) | 6.72% |
| Payout ratio (TTM) | 12.54% |
| EPS growth(5 years) | 18.67 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -13.71 |
More ▼
